Zhejiang Taimei Medical Technology Co., Ltd.
Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) Stock Overview
Explore Zhejiang Taimei Medical Technology Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2B
P/E Ratio
-8.34
EPS (TTM)
$-0.43
ROE
-0.21%
2576.HK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 49.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.55.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.34 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders. It offers software solutions, such as eCooperate, a clinical trial cooperation platform that optimizes clinical research operations management systems, as well as support decision-making with big data technology; eArchives, a clinical trial master file system; eCollect, an electronic data capture system; eCollege, a training management system; eQuality, an electronic quality audit system; eBalance, an interactive Web-based response system; eVisit Patient Reported Outcomes, a solution that enhances the ability of patients to enter data and the accuracy of clinical trial data; eTime, a project man-hour management system; and eImage, a medical image reading system. It also provides hospital software, including eTrial, a phase I ward management system; eSite, a clinical trial management system for GCP sites; GCP-X, an intelligent clinical trial platform; NomenCTMS, a clinical research project management system for GCP sites; eScreening, a subject information management and duplicate checking system; Intelligent Investigator, an initiated clinical trial platform; IIT-EDC, a clinical research data management platform; and Investigator-Initiated Clinical Trial Management System, a project management system. In addition, the company offers pharmacovigilance software solutions, such as eSafety global pharmacovigilance system; eSafety, an intelligent professional information system for pharmacovigilance; and SAE Manager, a safety data communication and management system for clinical trials. Further, it provides marketing software and digital innovation solutions. The company was founded in 2013 and is headquartered in Jiaxing, China.
Zhao Lu
627
No.9 Building, Jiaxing
1970